Personalized Ultrasound-Enhanced Drug Delivery System with AI, IoT, and Blockchain Integration

A novel system that integrates AI, IoT, and blockchain technologies to optimize ultrasound-enhanced drug delivery, ensuring personalized treatment, real-time monitoring, and secure supply chain management.

The original patent for ultrasound-enhanced delivery of drugs has limitations in terms of personalized treatment and supply chain management. The new inventive concept addresses these limitations by integrating AI, IoT, and blockchain technologies to create a more efficient, secure, and personalized system.

The new system consists of an AI-powered ultrasound transducer that generates tailored ultrasound waves based on a patient's eye anatomy, an IoT-enabled sensor that monitors eye pressure and temperature, a blockchain-enabled drug tracking module that verifies the authenticity and origin of the delivered drugs, and a machine learning-based controller that optimizes the ultrasound frequency and power based on real-time feedback. The system also includes a nanomaterial-based drug applicator, an AI-powered diagnostic module, and a cloud-based data analytics platform. The inventive concept enables real-time monitoring, personalized treatment, and secure supply chain management.

The new claims introduce the novel integration of AI, IoT, and blockchain technologies with ultrasound-enhanced drug delivery, providing a synergistic combination that significantly improves the original patent's limitations. The inventive step lies in the combination of these distinct technologies to create a more efficient, secure, and personalized system.

Alternative embodiments could include using different AI algorithms, IoT sensors, or blockchain platforms. Variations could also include integrating additional technologies, such as augmented reality or 5G networks, to further enhance the system's capabilities.

The inventive concept has significant commercial potential in the ophthalmic care industry, particularly in the treatment of diseases such as central retinal vein occlusion, branch retinal vein occlusion, and age-related macular degeneration. The system's ability to provide personalized treatment, real-time monitoring, and secure supply chain management makes it an attractive solution for healthcare providers and patients alike.